MedTrace Logo

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-04-16

No results posted yet for this study

Summary

The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are:

Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.

Conditions

  • Refractory B-Cell Lymphoma
  • B-cell Lymphoma Recurrent

Interventions

BIOLOGICAL

CAR-T cells therapy

CAR-T cells therapy

Sponsors & Collaborators

  • Spanish Clinical Research Network - SCReN

    collaborator NETWORK

  • Fundación Canaria de Investigación Sanitaria

    collaborator OTHER

  • Fundación para la Investigación Biomédica del Hospital 12 de Octubre

    collaborator UNKNOWN

  • Instituto de Investigación Biomédica de Salamanca

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2029-07-31
Completion
2030-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06378190 on ClinicalTrials.gov